SCHEMBL4584196

SCHEMBL4584196

CC(C)n1cc(-c2nc(C#N)c(N)nc2-c2ccccc2)ccc1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.50
ADORA1 P30542 3/20 0.50
USP8 P40818 1/20 0.49
ATR Q13535 7/20 0.40
BMPR1B O00238 1/20 0.39
BMPR1A P36894 1/20 0.39
TGFBR1 P36897 1/20 0.39
ACVRL1 P37023 1/20 0.39
ACVR1 Q04771 1/20 0.39
KDM5A P29375 3/20 0.38
KDM6B O15054 1/20 0.38
KDM5C P41229 1/20 0.38
KDM5D Q9BY66 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
PHF8 Q9UPP1 1/20 0.38
CHEK1 O14757 1/20 0.37
ABL1 P00519 1/20 0.37
PDGFRB P09619 1/20 0.37
PDGFRA P16234 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4584757 0.89 ADORA2A (0.64) ADORA2AADORA1USP8ATRBMPR1B
SCHEMBL4585338 0.88 ADORA2A (0.50) ADORA2AADORA1USP8ATRBMPR1B
SCHEMBL4584884 0.88 ADORA2A (0.51) ADORA2AADORA1USP8ATRBMPR1B
SCHEMBL4584195 0.87 ADORA1 (0.47) ADORA2AADORA1USP8ATRABL1
SCHEMBL4584141 0.87 USP8 (0.52) ADORA2AADORA1USP8ATRBMPR1B
SCHEMBL4585169 0.86 ADORA2A (0.57) ADORA2AADORA1ATRBMPR1BBMPR1A
SCHEMBL4585119 0.86 ADORA2A (0.46) ADORA2AADORA1USP8ATRABL1
SCHEMBL4585480 0.85 USP8 (0.48) ADORA2AADORA1USP8CHEK1ABL1
SCHEMBL4585208 0.85 ADORA2A (0.50) ADORA2AADORA1USP8ATRBMPR1B
SCHEMBL4584728 0.85 ADORA2A (0.47) ADORA2AADORA1USP8ATRBMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9518033-B2 (4E)-4-(4-substituted benzylideneamino)-2,3-dihydro-3-substituted-2-thioxothiazole-5-carbonitriles as A2AR antagonist and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-13 US disclosed
US-20150336912-A1 (4E)-4-(4-SUBSTITUTED BENZYLIDENEAMINO)-2,3-DIHYDRO-3-SUBSTITUTED-2-THIOXOTHIAZOLE-5-CARBONITRILES AS A2AR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-11-26 US disclosed
WO-2014106861-A1 (4E)-4-(4-SUBSTITUTED BENZYLIDENEAMINO)-2,3-DIHYDRO-3- SUBSTITUTED-2-THIOXOTHIAZOLE-5-CARBONITRILES AS A2AR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-07-10 WO disclosed
US-7407961-B2 Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2008-08-05 US disclosed
CN-1871231-A Pyrazine derivatives and pharmaceutical use thereof ASTELLAS PHARMA INC (JP) 2006-11-29 CN disclosed
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113387-A1 Pyrazine derivatives and pharmaceutical use thereof ADORA2A, P2RX5, ADORA1 ADORA2A 1/4885ADORA1 3/4885USP8 4884/4885
US-20150336912-A1 (4E)-4-(4-SUBSTITUTED BENZYLIDENEAMINO)-2,3-DIHYDRO-3-SUBSTITUTED-2-THIOXOTHIAZOLE-5-CARBONITRILES AS A2AR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF ADORA2A, ADORA2B, ADORA3 ADORA2A 1/4885ADORA1 4/4885USP8 3911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.